Across multiple studies in both diabetes and obesity populations, GLP-1 receptor agonists consistently improved mental health-related quality of life compared to placebo
Why GLP-1 coverage decisions are getting more complex Deciding whether to cover GLP-1s for weight loss can be challenging, especially given the significant costs involved
The modifications made to human GLP-1 include: Amino acid substitutions that resist DPP-4 enzyme degradation Attachment of fatty acid chains (acylation) as seen in semaglutide and liraglutide Fusion with immunoglobulin fragments (as in dulaglutide) to increase molecular size These changes are designed using rational drug design principles and implemented through biotechnology
The difference in absorption speed between sites is relatively modest for long-acting GLP-1 formulations
Sobo GLP-1 Weight Loss Plateaus Medically reviewed by Founder of Optimal Health Medical and physician specializing in holistic, integrative, and medical weight loss care.
European Bioinformatics Institute, European Molecular Biology Laboratory